Fundamentals of a personalized approach at different stages of newly diagnosed glaucoma
https://doi.org/10.21516/2072-0076-2024-17-2-121-127
Abstract
The review is focused on the adherence of glaucoma patients to the immediate start of treatment after the condition has been diagnosed. A personalized strategy, which includes the assessment of the patient's clinical and socio-economic status and the use of medications with proven efficacy, contributes to the formation of long-term adherence to therapy. In particular, the strategy combines preventive and diagnostic measures depending on the patient’s individual characteristics and involves their direct participation. Over 250 risk factors are known to reduce a patient’s adherence to treatment, whereas insufficient adherence can itself be considered as a risk factor for glaucoma progression. The asymptomatic course of the disease or the lack of a noticeable effect of drops instilled often cause the regimen to be violated, whilst the long-term therapy requires determination and self-control of the patient. Combined measures to improve the adherence are based on the specific needs of the patients and are consistent with their lifestyle. As a rule, the patients need special instruction, good means of communication with the doctor, simplified treatment regimens, and an adequate interaction with the public health facilities. Importantly, the therapy start depends not only on the level of intraocular pressure, but also on the stage of the glaucomatous process at which it was first diagnosed.
About the Authors
S. А. Zubasheva
Treatment and Diagnostic Center #9
Russian Federation
Russian Federation
Svetlana A. Zubasheva — ophthalmologist
15/18, Bldg. 1, B. Pirogovskaya St., Moscow, 119021
T. V. Chernyakova
Medical Center of Bank of Russia
Russian Federation
Russian Federation
Tatyana V. Chernyakova — Cand. of Med. Sci., ophthalmologist
66, Sevastopolsky Ave., Moscow, 117593
D. A. Baryshnikova
Gazprom Polyclinic #1
Russian Federation
Russian Federation
Darya A. Baryshnikova — ophthalmologist
19, Bldg. 4, Michurinsky Ave., Moscow, 119192
A. V. Kuroyedov
Mandryka Central Clinical Hospital;
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Alexander V. Kuroyedov — Dr. of Med. Sci., head of ophthalmological center; professor of chair of ophthalmology
8А, Bolshaya Olenya St., Moscow, 107014;
1, Ostrovityanov St., Moscow, 11799
References
1. Ramesh PV, Parthasarathi S, John RK. An exploratory study of compliance to anti-glaucoma medications among literate primary glaucoma patients at an urban tertiary eye care center in South India. Indian J Ophthalmol. 2021; 69 (6): 1418–24. doi: 10.4103/ijo.IJO_2008_20
2. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 2081–90. doi: 10.1016/j.ophtha.2014.05.013
3. World report on vision. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Available at: https://whodc.mednet.ru/ru/osnovnye-publikaczii/glaznye-bolezni/3137/visit.html?link_name=apps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F328717%2F9789241516570-eng.pdf/ (Accessed 08.03.2023)
4. De Moraes CG, Liebmann JM, Levin LA. Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Prog Retin Eye Res. 2017; 56: 107–47. doi: 10.1016/j.preteyeres.2016.10.001
5. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90 (3): 262–7. doi: 10.1136/bjo.2005.081224
6. Erichev V.P. Challenges of long-term glaucoma therapy. Vestnik oftal’mologii. 2021; 137 (5–2): 354–60 (In Russ.). doi:10.17116/oftalma2021137052354
7. Makogon S.I., Makogon A.S. Analysis of the causes of low adherence to treatment in patients of primary open-angle glaucoma. Vestnik sovremennoj klinicheskoj mediciny. 2015; 8 (6): 52–7 (In Russ.). doi:10.20969/vskm.2015.8(6).52-57
8. Korelina V.E., Gazizova I.R. Age-related aspects of adherence to glaucoma therapy. Effective pharmacotherapy. 2021; 17 (37): 34–9 (In Russ.). doi: 10.33978/2307-3586-2021-17-37-34-39
9. Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: A cross-sectional survey. Ophthalmology. 2015; 122 (7): 1308–16. doi: 10.1016/j.ophtha.2015.03.026
10. Wolfram C, Stahlberg E, Pfeiffer N. Patient-reported nonadherence with glaucoma therapy. J Ocul Pharmacol Ther. 2019; 35 (4): 223–8. doi: 10.1089/jop.2018.0134
11. Spencer SKR, Shulruf B, McPherson ZE, et al. Factors affecting adherence to topical glaucoma therapy: A quantitative and qualitative pilot study analysis in Sydney, Australia. Ophthalmol Glaucoma. 2019; 2 (2): 86–93. doi: 10.1016/j.ogla.2019.01.006
12. Lovpache D.N., Zavadski P.C., Zvereva O.G., et al. Compliance and persistence in patients with primary open-angle glaucoma through the doctor opinions. National journal Glaucoma. 2020; 19 (2): 11–21 (In Russ.). doi: 10.25700/NJG.2020.02.02
13. Achilleos M, Merkouris A, Charalambous A, Papastavrou E. Medication adherence, self-efficacy and health literacy among patients with glaucoma: a mixed-methods study protocol. BMJ Open. 2021; 11 (1): e039788. doi: 10.1136/bmjopen-2020-039788
14. Petrov S.Ju., Lovpache Dzh.N, Brezhnev A.Ju. Principles of treatment adherence among patients with glaucoma according to the IV edition of the European Glaucoma Guidelines (analytical commentary). RMJ Clinical ophthalmology. 2015; 16 (3): 152–4 (In Russ.).
15. Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011; 118 (12): 2398–402. doi: 10.1016/j.ophtha.2011.05.013
16. Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. Eye (Lond). 2009; 23 (4): 924–32. doi:10.1038/eye.2008.103
17. Koroljova I.A., Oganezova Zh.G. Therapy of chronic diseases in ophthalmology: compliance issues. RMJ Clinical ophthalmology. 2016; 1: 59–63 (In Russ.).
18. Volkova N.V., Zavadsky P.C., Kuroyedov A.V., et al. Hypotensive regimens providing target intraocular pressure in patients with primary open-angle glaucoma (results of a multicenter analytical study). National journal Glaucoma. 2019; 18 (4): 44–59 (In Russ.). doi: 10.25700/10.25700/NJG.2019.04.04
19. Abysheva L.D., Avdeev R.V., Alexandrov A.S., et al. The effect of local hypotensive glaucoma therapy on the development and progression of dry eye syndrome. RMJ Clinical ophthalmology. 2017; (2): 74–82 (In Russ.). doi:10.21689/2311-7729-2017-17-2-74-82
20. Dorofeev D.A., Brezhnev A.Yu., Gazizova I.R., et al. Prerequisites to use preservative-free drugs in medication therapy of glaucoma. Ophthalmology in Russia. 2021; 18 (3): 532–8 (In Russ.). doi: 10.18008/1816-5095-2021-3-532-538
21. Stringham J, Ashkenazy N, Galor A, Wellik SR. Barriers to glaucoma medication compliance among veterans: Dry eye symptoms and anxiety disorders. Eye Contact Lens. 2018; 44 (1): 50–4. doi: 10.1097/ICL.0000000000000301
22. Tapply I, Broadway DC. Improving adherence to topical medication in patients with glaucoma. Patient prefer adherence. 2021; 15: 1477–89. doi: 10.2147/PPA.S264926
23. Onufrijchuk O.N., Gazizova I.R., Kuroedov A.V., Seleznev A.V. The effect of the main active substances of hypotensive drops on the eye condition of patients with glaucoma. Pacific Medical Journal. 2020; 3 (81): 5–10 (In Russ.). doi: 10.34215%2F1609-1175-2020-3-5-10
24. Diordiychuk S.V., Kuroyedov A.V., Fomin N.E., et al. Timely diagnosis and the effect of treatment adherence on the prognosis and progression of glaucoma optic neuropathy. RMJ Clinical ophthalmology. 2021; 21 (1): 34–9 (In Russ.). doi:10.32364/2311-7729-2021-21-1-34-39
25. Neroyev V.V., Zolotarev A.V., Karlova E.V., et al. Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting. Vestnik oftal’mologii. 2019; 135 (6): 42–51 (In Russ.). doi: 10.17116/oftalma201913506142
26. Makogon S.I., Onishhenko A.L., Makogon A.S. Adherence to treatment in elderly and senile persons with primary open-angle glaucoma. National journal Glaucoma. 2019; 18 (4): 3–13 (In Russ.). doi: 10.25700/NJG.2019.04.01
27. Sanchez FG, Mansberger SL, Newman-Casey PA. Predicting adherence with the glaucoma treatment compliance assessment tool. Journal of glaucoma. 2020; 29 (11): 1017–24. doi: 10.1097/IJG.0000000000001616
28. Korneeva A.V., Kuroyedov A.V., Zavadski P.C., et al. Adherence to glaucoma hypotensive therapy: patients' opinions on key factors of low compliance. Analytical multi-central study results. National journal Glaucoma. 2020; 19 (3): 12–21 (In Russ.). doi: 10.25700/NJG.2020.03.02
29. Alekseev I.В., Lindenbraten A.L., Aliverdieva M.A., Panina E.N., Sokolov I.M. Evaluation of the effectiveness of the organization of the system of early detection and monitoring of primary open-angle glaucoma. Glaucoma News. 2016; 1: 37 (In Russ.).
30. Kuleshova N.A., Burja R.A., Sorokin E.L. The proportion of newly diagnosed glaucoma among patients applying to the diagnostic and treatment department, the causes and ways to solve them. Modern technologies in ophthalmology. 2019; 2: 66–9 (In Russ.). doi:10.25276/2312-4911-2019-2-66-69
31. Kuroyedov A.V., Movsisyan A.B., Egorov E.A., et al. The profile of patients with primary open-angle glaucoma in the Russian Federation. National journal Glaucoma. 2021; 20 (1): 3–15 (In Russ.). doi: 10.25700/NJG.2021.01.01
32. Avdeev R.V., Alexandrov A.S., Bakunina N.A., et al. Comparison of treatment regimens for patients with primary open-angle glaucoma with signs of disease progression. Part 1. IOP levels. National journal Glaucoma. 2018; 17 (1): 14–28 (In Russ.). doi: 10.25700/NJG.2018.01.02
33. Frech S, Kreft D, Guthoff RF, Doblhammer G. Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients — an observational cohort study. PLoS One. 2018; 13 (1): e0191185. doi: 10.1371/journal.pone.0191185
34. Salman M, Andrews C, Heisler M, Darnley-Fisch D, Newman-Casey PA. Psychosocial predictors of glaucoma medication adherence among the Support, Educate, Empower (SEE) personalized glaucoma coaching pilot study participants. Am J Ophthalmol. 2020; 216: 207–18. doi: 10.1016/j.ajo.2020.02.009
35. Amdie FZ, Sawhney M, Woo K. The weakness of will: The role of free will in treatment adherence. Patient prefer adherence. 2022; 16: 1131–9. doi: 10.2147/PPA.S362706.doi:10.2147/PPA.S362706
36. Avdeev R.V., Alexandrov A.S., Bakunina N.A., et al. Prediction of disease duration and age of patients with different primary open-angle glaucoma changes. National journal Glaucoma. 2014; 13 (2): 60–9 (In Russ.).
37. Chang DS, Friedman DS, Frazier T, Plyler R, Boland MV. Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Ophthalmology. 2013; 120 (7): 1396–402. doi: 10.1016/j.ophtha.2013.01.002
38. Boland MV, Chang DS, Frazier T, Plyler R, Friedman DS. Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study. JAMA Ophthalmol. 2014; 132 (7): 838–44. doi: 10.1001/jamaophthalmol.2014.856. PMID: 24830878
39. Zaharia AC, Dumitrescu OM, Radu M, Rogoz RE. Adherence to therapy in glaucoma treatment. A Review. J Pers Med. 2022; 12 (4): 514. doi: 10.3390/jpm12040514
40. Miller DJ, Niziol LM, Elam AR, et al. Demographic, clinical, and psychosocial predictors of change in medication adherence in the support, educate, empower program. Ophthalmol Glaucoma. 2022; 5 (1): 47–57. doi: 10.1016/j.ogla.2021.06.001
41. Gabdrakhmanov L.M., Gazizova I.R., Seleznev A.V., et al. The psychology of a glaucoma patient. Russian ophthalmological journal. 2020; 13 (3): 92–6 (In Russ.). https://doi.org/10.21516/2072-0076-2020-13-3-92-96
42. Gatwood J, Brooks C, Meacham R, et al. Facilitators and barriers to glaucoma medication adherence. J Glaucoma. 2022; 31 (1): 31–6. doi: 10.1097/IJG.0000000000001965
43. Sangilbaeva Zh.O., Aringazina A.M. Compliance in the treatment of patients with glaucoma. Herald of the Kazakh national medical university. 2020 (1): 160–1 (In Russ.).
44. Hamid MS, Valicevic A, Brenneman B, et al. Text parsing-based identification of patients with poor glaucoma medication adherence in the electronic health record. Am J Ophthalmol. 2021; 222: 54–9. doi: 10.1016/j.ajo.2020.09.008
45. Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology. 2009; 116 (12): 2286–93. doi: 10.1016/j.ophtha.2009.05.026
46. Killeen OJ, Niziol LM, Cho J, et al. Glaucoma medication adherence 1 year after the support, educate, empower personalized glaucoma coaching program. Ophthalmol Glaucoma. 2023; 6 (1): 23–8. doi: 10.1016/j.ogla.2022.08.001
47. Lai Y, Wu Y, Chai C, et al. The effect of patient education and telemedicine reminders on adherence to eye drops for glaucoma. Ophthalmol Glaucoma. 2020; 3 (5): 369–76. doi: 10.1016/j.ogla.2020.05.005
48. Abulkasimova Kh.Kh. Evaluation of the mobile applications efficiency in compliance control in patients with glaucoma. Modern technologies in ophtalmology. 2021; 2: 105–10 (In Russ.). https://doi.org/10.25276/2312-4911-2021-2-105-110
49. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008; 115 (8): 1320–7. doi: 10.1016/j.ophtha.2007.11.023
50. Aguilar-Rivera M, Erudaitius DT, Wu VM, et al. Smart electronic eyedrop bottle for unobtrusive monitoring of glaucoma medication adherence. Sensors (Basel). 2020; 20 (9): 2570. doi: 10.3390/s20092570
51. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15 (6): 22–33.
52. McClelland JF, Bodle L, Little JA. Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes. Patient Prefer Adherence. 2019; 13: 431–9. doi: 10.2147/PPA.S176412
53. Quigley HA. 21st century glaucoma care. Eye (Lond). 2019; 33 (2): 254–60. doi: 10.1038/s41433-018-0227-8
54. Varadaraj V, Kahook MY, Ramulu PY, Pitha IF. Patient acceptance of sustained glaucoma treatment strategies. J Glaucoma. 2018; 27 (4): 328–35. doi: 10.1097/IJG.0000000000000913
55. Lewis RA, Christie WC, Day DG, et al.; Bimatoprost SR Study Group. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II Clinical trial. Am J Ophthalmol. 2017; 175: 137–47. doi: 10.1016/j.ajo.2016.11.020
56. Brandt JD, DuBiner HB, Benza R, et al.; Collaborators. Long-term safety and efficacy of a sustained-release Bimatoprost ocular ring. Ophthalmology. 2017; 124 (10): 1565–6. doi: 10.1016/j.ophtha.2017.04.022
57. Shirley M. Bimatoprost implant: First approval. Drugs Aging. 2020; 37 (6): 457–62. doi: 10.1007/s40266-020-00769-8
58. Rahić O, Tucak A, Omerović N, et al. Novel drug delivery systems fighting glaucoma: Formulation obstacles and solutions. Pharmaceutics. 2020; 13 (1): 28. doi: 10.3390/pharmaceutics13010028
59. Lazreg S, Merad Z, Nouri MT, et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. J Fr Ophtalmol. 2018; 41 (10): 945–54. doi: 10.1016/j.jfo.2018.04.012
60. Negri L, Ferreras A, Iester M. Timolol 0.1 % in glaucomatous patients: efficacy, tolerance, and quality of life. J Ophthalmol. 2019; 2019: 1–12. doi: 10.1155/2019/4146124
61. Samy KE, Cao Y, Kim J, et al. Co-delivery of Timolol and Brimonidine with a polymer thin-film intraocular device. J Ocul Pharmacol Ther. 2019; 35 (2): 124–31. doi: 10.1089/jop.2018.0096
62. Kuroyedov A.V., Brezhnev A.Yu., Lovpache J.N., et al. The feasibility of adopting stepwise initial approaches in treatment of patients with different stages of glaucoma. National journal Glaucoma. 2018; 17 (4): 27–54 (In Russ.). doi: 10.25700/NJG.2018.04.03
63. Kuroedov A.V., Brezhnev A.Ju., Aleksandrov A.S. How to lower the level of intraocular pressure by 30 % in patients with glaucoma (Literature review). Voenno-medicinskij zhurnal. 2009; 330 (6): 40–6 (In Russ.). doi:10.17816/RMMJ74881
64. Onishhenko A.L., Isakov I.N., Kolbasko A.V., Makogon S.I. Initial combination therapy of primary open-angle glaucoma. Vestnik oftal’mologii. 2019; 135 (2): 32–8 (In Russ.). doi: 10.17116/oftalma201913502132
65. Clinical guidelines — Primary open-angle glaucoma — 2020 (16.02.2021) (In Russ.). URL:https://diseases.medelement.com/disease/глаукома-первичная-открытоугольная-кп-рф-2020/16853/ (Accessed 08.03.2023)
Review
For citations:
Zubasheva S.А., Chernyakova T.V., Baryshnikova D.A., Kuroyedov A.V. Fundamentals of a personalized approach at different stages of newly diagnosed glaucoma. Russian Ophthalmological Journal. 2024;17(2):121-127. (In Russ.) https://doi.org/10.21516/2072-0076-2024-17-2-121-127
Views:
608
Email this article 